Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorVA Sierra Nevada Health Care System
About this trial
The investigators will evaluate the immune response of immunocompromised adults, who have previously received at least 1 dose of 23-valent pneumococcal polysaccharide vaccine, to the booster with of 21-valent pneumococcal conjugate vaccine . Immune response will be assessed by opsonophagocytic assay reactivity.
Eligibility criteria
Qualifiers
Subject meets the CDC definition of an immunocompromising condition
Have received at least 1 dose of PPSV23
Disqualifiers
Less than 5 years since last receipt of PPSV23 validated to patient medical record and Immunize Nevada Website
Previous administration of PCV20
Previous administration of PCV13
Previous administration of PCV15
Trial design
Treatments tested in this trial
- 21-valent pneumococcal conjugate vaccine
Treatment groups
45 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
VA Sierra Nevada Health Care System
Lead sponsor
Merck Sharp & Dohme LLC
Collaborator
Source ClinicalTrials.gov